Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIORA THERAPEUTICS, INC.BIOR · Entity 85047 | Director | January 03, 2023 | January 05, 2023 |
| Penumbra IncPEN · Entity 3430 | Director | February 13, 2026 | February 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIORA THERAPEUTICS, INC.
Report date January 03, 2023 · Filed January 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Series X Preferred StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-01-03 transaction · row 1
1 source rowRow 1 · 2023-01-03 · Disposition to issuer · Disposed 8 · Balance 0 F1: On November 10, 2022, the Company's board of directors (the "Board") declared a dividend of one one-thousandth of a share of Series X Preferred Stock, par value $0.001 per share (the "Preferred Stock"), for each outstanding share of common stock to common stockholders of record at 5:00 p.m. Eastern Time on November 21, 2022, in a transaction exempt from Section 16 under Rule 16a-9. The shares of Preferred Stock were distributed on November 21, 2022. As a result, the Reporting Person received the shares of Preferred Stock set forth above. The Preferred Stock was not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company. F2: On January 3, 2023, in connection with the Company's reverse stock split for the common stock, the shares of Preferred Stock were redeemed automatically in accordance with the certificate of designation of the Preferred Stock. Each share of Preferred Stock was redeemed in consideration for the right to receive an amount equal to $0.001 in cash (rounded to the nearest cent) for each whole share of Preferred Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: On November 10, 2022, the Company's board of directors (the "Board") declared a dividend of one one-thousandth of a share of Series X Preferred Stock, par value $0.001 per share (the "Preferred Stock"), for each outstanding share of common stock to common stockholders of record at 5:00 p.m. Eastern Time on November 21, 2022, in a transaction exempt from Section 16 under Rule 16a-9. The shares of Preferred Stock were distributed on November 21, 2022. As a result, the Reporting Person received the shares of Preferred Stock set forth above. The Preferred Stock was not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company.
F2: On January 3, 2023, in connection with the Company's reverse stock split for the common stock, the shares of Preferred Stock were redeemed automatically in accordance with the certificate of designation of the Preferred Stock. Each share of Preferred Stock was redeemed in consideration for the right to receive an amount equal to $0.001 in cash (rounded to the nearest cent) for each whole share of Preferred Stock.
Penumbra Inc
Report date February 13, 2026 · Filed February 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,293 |
Reported balance
After 2026-02-13 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-02-13 · Grant · Acquired 589 · Balance 4,293 F1: Restricted stock units (RSUs) vest as to 1/4 on each of March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026, subject to Ms. Sarna's continued service as director through such dates. Notwithstanding the foregoing, if the Closing (as defined in that certain Agreement and Plan of Merger, dated as of January 14, 2026, among the Issuer, Boston Scientific Corporation, a Delaware corporation, and Pinehurst Merger Sub, Inc., a Delaware corporation) occurs, any of the RSUs that remain unvested will fully vest on the Closing, subject to Ms. Sarna's continued service as director through such date. F2: A portion of these shares is subject to vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units (RSUs) vest as to 1/4 on each of March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026, subject to Ms. Sarna's continued service as director through such dates. Notwithstanding the foregoing, if the Closing (as defined in that certain Agreement and Plan of Merger, dated as of January 14, 2026, among the Issuer, Boston Scientific Corporation, a Delaware corporation, and Pinehurst Merger Sub, Inc., a Delaware corporation) occurs, any of the RSUs that remain unvested will fully vest on the Closing, subject to Ms. Sarna's continued service as director through such date.
F2: A portion of these shares is subject to vesting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 13, 2026 Filed Feb 18, 2026 20:04 UTC | Penumbra Inc PEN · Entity 3430 | GrantCommon Stock | 589 | $0.00 | $0.00 |
DisclosureSEC source: 0001781561-26-000002 · wk-form4_1771463043.xml · nonDerivative · entry 1 Sarna Surbhi · CIK 0001781561 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,293 F1 · shares: Restricted stock units (RSUs) vest as to 1/4 on each of March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026, subject to Ms. Sarna's continued service as director through such dates. Notwithstanding the foregoing, if the Closing (as defined in that certain Agreement and Plan of Merger, dated as of January 14, 2026, among the Issuer, Boston Scientific Corporation, a Delaware corporation, and Pinehurst Merger Sub, Inc., a Delaware corporation) occurs, any of the RSUs that remain unvested will fully vest on the Closing, subject to Ms. Sarna's continued service as director through such date. F2 · balance_after: A portion of these shares is subject to vesting. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 19:39 UTC | Penumbra Inc PEN · Entity 3430 | GrantCommon Stock | 744 | $0.00 | $0.00 |
DisclosureSEC source: 0001321732-25-000029 · wk-form4_1740011984.xml · nonDerivative · entry 1 Sarna Surbhi · CIK 0001781561 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,704 F1 · shares: Restricted stock units vest as to 1/4 on each of March 31, 2025, June 30, 2025, September 30, 2025, and December 31, 2025, subject to Ms. Sarna's continued service as director through such dates. F2 · balance_after: A portion of these shares is subject to vesting. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 19:40 UTC | Penumbra Inc PEN · Entity 3430 | GrantCommon Stock | 665 | $0.00 | $0.00 |
DisclosureSEC source: 0001321732-24-000010 · wk-form4_1708562391.xml · nonDerivative · entry 1 Sarna Surbhi · CIK 0001781561 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,960 F1 · shares: Restricted stock units vest as to 1/4 on each of March 31, 2024, June 30, 2024, September 30, 2024, and December 31, 2024, subject to Ms. Sarna's continued service as director through such dates. F2 · balance_after: A portion of these shares is subject to vesting. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 19:36 UTC | Penumbra Inc PEN · Entity 3430 | SaleCommon Stock | 85 | $247.68 | $21,052.80 |
DisclosureSEC source: 0001321732-24-000004 · wk-form4_1704414958.xml · nonDerivative · entry 1 Sarna Surbhi · CIK 0001781561 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,295 F1 · kind: The sales were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 19:34 UTC | Penumbra Inc PEN · Entity 3430 | SaleCommon Stock | 85 | $240.99 | $20,484.15 |
DisclosureSEC source: 0001321732-23-000116 · wk-form4_1696462447.xml · nonDerivative · entry 1 Sarna Surbhi · CIK 0001781561 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,380 F1 · kind: The sales were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · balance_after: A portion of these shares is subject to vesting. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 20:01 UTC | Penumbra Inc PEN · Entity 3430 | SaleCommon Stock | 85 | $266.62 | $22,662.70 |
DisclosureSEC source: 0001321732-23-000104 · wk-form4_1694044863.xml · nonDerivative · entry 1 Sarna Surbhi · CIK 0001781561 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,465 F1 · kind: The sales were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · balance_after: A portion of these shares is subject to vesting. Read SEC document |
| July 03, 2023 Filed Jul 6, 2023 20:23 UTC | Penumbra Inc PEN · Entity 3430 | SaleCommon Stock | 27 | $341.45 | $9,219.15 |
DisclosureSEC source: 0001321732-23-000080 · wk-form4_1688689423.xml · nonDerivative · entry 1 Sarna Surbhi · CIK 0001781561 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,550 F1 · kind: The sales were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · balance_after: A portion of these shares is subject to vesting. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 19:31 UTC | Penumbra Inc PEN · Entity 3430 | SaleCommon Stock | 28 | $276.37 | $7,738.36 |
DisclosureSEC source: 0001321732-23-000046 · wf-form4_168073746563449.xml · nonDerivative · entry 1 Sarna Surbhi · CIK 0001781561 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,577 F1 · kind: The sales were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · balance_after: A portion of these shares is subject to vesting. Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 19:45 UTC | Penumbra Inc PEN · Entity 3430 | GrantCommon Stock | 680 | $0.00 | $0.00 |
DisclosureSEC source: 0001321732-23-000024 · wf-form4_167711312740114.xml · nonDerivative · entry 1 Sarna Surbhi · CIK 0001781561 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,605 F1 · shares: Restricted stock units vest as to 1/4 on each of March 31, 2023, June 30, 2023, September 30, 2023, and December 31, 2023, subject to Ms. Sarna's continued service as director through such dates. F2 · balance_after: A portion of these shares is subject to vesting. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 19:05 UTC | Penumbra Inc PEN · Entity 3430 | SaleCommon Stock | 27 | $227.12 | $6,132.24 |
DisclosureSEC source: 0001321732-23-000002 · wf-form4_167296349821741.xml · nonDerivative · entry 1 Sarna Surbhi · CIK 0001781561 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,925 F1 · kind: The sales were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · balance_after: A portion of these shares is subject to vesting. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 16:05 UTC | BIORA THERAPEUTICS, INC. BIOR · Entity 85047 | Disposition to issuerSeries X Preferred Stock | 8 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-000959 · doc4.xml · nonDerivative · entry 1 Sarna Surbhi · CIK 0001781561 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: On November 10, 2022, the Company's board of directors (the "Board") declared a dividend of one one-thousandth of a share of Series X Preferred Stock, par value $0.001 per share (the "Preferred Stock"), for each outstanding share of common stock to common stockholders of record at 5:00 p.m. Eastern Time on November 21, 2022, in a transaction exempt from Section 16 under Rule 16a-9. The shares of Preferred Stock were distributed on November 21, 2022. As a result, the Reporting Person received the shares of Preferred Stock set forth above. The Preferred Stock was not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company. F2 · shares: On January 3, 2023, in connection with the Company's reverse stock split for the common stock, the shares of Preferred Stock were redeemed automatically in accordance with the certificate of designation of the Preferred Stock. Each share of Preferred Stock was redeemed in consideration for the right to receive an amount equal to $0.001 in cash (rounded to the nearest cent) for each whole share of Preferred Stock. F2 · price: On January 3, 2023, in connection with the Company's reverse stock split for the common stock, the shares of Preferred Stock were redeemed automatically in accordance with the certificate of designation of the Preferred Stock. Each share of Preferred Stock was redeemed in consideration for the right to receive an amount equal to $0.001 in cash (rounded to the nearest cent) for each whole share of Preferred Stock. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 20:32 UTC | Penumbra Inc PEN · Entity 3430 | SaleCommon Stock | 28 | $191.20 | $5,353.60 |
DisclosureSEC source: 0001321732-22-000087 · wf-form4_166501635608599.xml · nonDerivative · entry 1 Sarna Surbhi · CIK 0001781561 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,952 F1 · kind: The sales were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · balance_after: A portion of these shares is subject to vesting. Read SEC document |
| July 05, 2022 Filed Jul 5, 2022 18:48 UTC | BIORA THERAPEUTICS, INC. BIOR · Entity 85047 | SaleCommon Stock | 7,517 | $0.61 | $4,585.37 |
DisclosureSEC source: 0000899243-22-025094 · doc4.xml · nonDerivative · entry 1 Sarna Surbhi · CIK 0001781561 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,774 F1 · kind: The proceeds of this sale are intended to assist the Reporting Person in satisfying income tax obligations resulting from the vesting and settlement of restricted stock units. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 20:26 UTC | Penumbra Inc PEN · Entity 3430 | SaleCommon Stock | 27 | $124.39 | $3,358.53 |
DisclosureSEC source: 0001321732-22-000063 · wf-form4_165715357844797.xml · nonDerivative · entry 1 Sarna Surbhi · CIK 0001781561 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,980 F1 · kind: The sales were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · balance_after: A portion of these shares is subject to vesting. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 16:30 UTC | BIORA THERAPEUTICS, INC. BIOR · Entity 85047 | GrantStock Option (Right to Buy) · Derivative | 148,810 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0000899243-22-023089 · doc4.xml · derivative · entry 2 Sarna Surbhi · CIK 0001781561 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,810 Underlying: Common Stock · 148,810 shares Expires 2032-06-15 F2 · deemedExecutionDate: This option represents the right to purchase 148,810 shares of the Issuer's common stock, which vest in full on the earlier of (1) June 15, 2023 or (2) the date of the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. F2 · derivative.exercise_date: This option represents the right to purchase 148,810 shares of the Issuer's common stock, which vest in full on the earlier of (1) June 15, 2023 or (2) the date of the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 16:30 UTC | BIORA THERAPEUTICS, INC. BIOR · Entity 85047 | GrantCommon Stock | 96,154 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-023089 · doc4.xml · nonDerivative · entry 1 Sarna Surbhi · CIK 0001781561 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,291 F1 · shares: Represents 96,154 restricted stock units, which vest in full on the earlier of (1) June 15, 2023 or (2) the date of the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 19:50 UTC | Penumbra Inc PEN · Entity 3430 | SaleCommon Stock | 28 | $221.71 | $6,207.88 |
DisclosureSEC source: 0001321732-22-000035 · wf-form4_164920259840150.xml · nonDerivative · entry 1 Sarna Surbhi · CIK 0001781561 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,007 F1 · kind: The sales were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · balance_after: A portion of these shares is subject to vesting. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 20:59 UTC | Penumbra Inc PEN · Entity 3430 | GrantCommon Stock | 710 | $0.00 | $0.00 |
DisclosureSEC source: 0001321732-22-000027 · wf-form4_164566792743141.xml · nonDerivative · entry 1 Sarna Surbhi · CIK 0001781561 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,035 F1 · shares: Restricted stock units vest as to 1/4 on each of March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022, subject to Ms. Sarna's continued service as director through such dates. F2 · balance_after: A portion of these shares is subject to vesting. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 19:46 UTC | Penumbra Inc PEN · Entity 3430 | SaleCommon Stock | 94 | $285.34 | $26,821.96 |
DisclosureSEC source: 0001321732-22-000008 · wf-form4_164142994409565.xml · nonDerivative · entry 1 Sarna Surbhi · CIK 0001781561 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,325 F1 · kind: The sales were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · balance_after: A portion of these shares is subject to vesting. Read SEC document |
| November 01, 2021 Filed Nov 2, 2021 19:47 UTC | Penumbra Inc PEN · Entity 3430 | SaleCommon Stock | 907 | $278.06 | $252,200.42 |
DisclosureSEC source: 0001321732-21-000104 · wf-form4_163589682382643.xml · nonDerivative · entry 1 Sarna Surbhi · CIK 0001781561 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,419 F1 · kind: The sales were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · balance_after: A portion of these shares is subject to vesting. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 18:34 UTC | BIORA THERAPEUTICS, INC. PROG · Entity 85047 | GrantStock Option (Right to Buy) · Derivative | 96,456 | $0.00 Strike: $3.41 | $0.00 |
DisclosureSEC source: 0000899243-21-027614 · doc4.xml · derivative · entry 2 Sarna Surbhi · CIK 0001781561 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,456 Underlying: Common Stock · 96,456 shares Expires 2031-07-01 F2 · deemedExecutionDate: This option represents the right to purchase 96,456 shares of the Issuer's common stock, which vest in equal installments on the first, second, third and fourth anniversaries of July 1, 2021, subject to the Reporting Person's continued service to the Issuer. F2 · derivative.exercise_date: This option represents the right to purchase 96,456 shares of the Issuer's common stock, which vest in equal installments on the first, second, third and fourth anniversaries of July 1, 2021, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 18:34 UTC | BIORA THERAPEUTICS, INC. PROG · Entity 85047 | GrantCommon Stock | 60,137 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-027614 · doc4.xml · nonDerivative · entry 1 Sarna Surbhi · CIK 0001781561 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,137 F1 · shares: Represents 60,137 restricted stock units, which vest in equal installments on the first, second, third and fourth anniversaries of July 1, 2021, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 20:56 UTC | Penumbra Inc PEN · Entity 3430 | GrantCommon Stock | 535 | $0.00 | $0.00 |
DisclosureSEC source: 0001321732-21-000026 · wf-form4_161413175692177.xml · nonDerivative · entry 1 Sarna Surbhi · CIK 0001781561 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,326 F1 · shares: Restricted stock units vest as to 1/4 on each of March 31, 2021, June 30, 2021, September 30, 2021, and December 31, 2021, subject to Ms. Sarna's continued service as director through such dates. F2 · balance_after: A portion of these shares is subject to vesting. Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 20:32 UTC | Penumbra Inc PEN · Entity 3430 | GrantCommon Stock | 756 | $0.00 | $0.00 |
DisclosureSEC source: 0001321732-20-000029 · wf-form4_158164390553328.xml · nonDerivative · entry 1 Sarna Surbhi · CIK 0001781561 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,791 F1 · shares: Restricted stock units vest as to 1/4 on each of March 31, 2020, June 30, 2020, September 30, 2020, and December 31, 2020, subject to Ms. Sarna's continued service as director through such dates. F2 · balance_after: A portion of these shares is subject to vesting. Read SEC document |
| January 27, 2020 Filed Jan 29, 2020 20:04 UTC | Penumbra Inc PEN · Entity 3430 | SaleCommon Stock | 273 | $168.79 | $46,079.67 |
DisclosureSEC source: 0001321732-20-000009 · wf-form4_158034627214587.xml · nonDerivative · entry 1 Sarna Surbhi · CIK 0001781561 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,035 F1 · kind: The sales were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · balance_after: A portion of these shares is subject to vesting. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 19:50 UTC | Penumbra Inc PEN · Entity 3430 | GrantCommon Stock | 436 | $0.00 | $0.00 |
DisclosureSEC source: 0001321732-19-000078 · wf-form4_156219779941468.xml · nonDerivative · entry 2 Sarna Surbhi · CIK 0001781561 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,308 F3 · shares: Restricted stock units vest as to 1/2 on each of September 30, 2019 and December 31, 2019, subject to Ms. Sarna's continued service as a director through such dates. F2 · balance_after: A portion of these shares is subject to vesting. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 19:50 UTC | Penumbra Inc PEN · Entity 3430 | GrantCommon Stock | 872 | $0.00 | $0.00 |
DisclosureSEC source: 0001321732-19-000078 · wf-form4_156219779941468.xml · nonDerivative · entry 1 Sarna Surbhi · CIK 0001781561 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 872 F1 · shares: Restricted stock units vest as to 1/16 in approximately equal quarterly installments on the last day of each calendar quarter starting with the calendar quarter ending September 30, 2019, subject to Ms. Sarna's continued service as a director through such dates. F2 · balance_after: A portion of these shares is subject to vesting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.